Presenting clinical data at prestigious conferences like the AAN Annual Meeting and the Eilat Conference significantly boosts the visibility of Longboard Pharmaceuticals' research and development efforts in the field of antiepileptic drugs. This can positively influence investor perception and potentially increase stock value in the short term due to heightened anticipation of successful drug development and future commercialization.